MedPath

Veloce BioPharma LLC

Veloce BioPharma LLC logo
🇺🇸United States
Ownership
Private
Established
2015-01-01
Employees
1
Market Cap
-
Website
https://velocebiopharma.com

Clinical Trials

6

Active:2
Completed:3

Trial Phases

1 Phases

Phase 2:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (100.0%)

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Phase 2
Conditions
Warts
Interventions
Drug: Placebo Gel (no Povidone-Iodine)
First Posted Date
2020-02-05
Last Posted Date
2021-04-01
Lead Sponsor
Veloce BioPharma LLC
Target Recruit Count
90
Registration Number
NCT04253912
Locations
🇺🇸

Veloce BioPharma Clinical Trial Site, Lynchburg, Virginia, United States

A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Phase 2
Completed
Conditions
Chemotherapy-Associated Paronychia
Interventions
First Posted Date
2017-07-05
Last Posted Date
2019-01-25
Lead Sponsor
Veloce BioPharma LLC
Target Recruit Count
102
Registration Number
NCT03207906
Locations
🇺🇸

Compassionate Cancer Care, Fountain Valley, California, United States

🇺🇸

Northwestern University Department of Dermatology, Chicago, Illinois, United States

🇺🇸

Washington University, Saint Louis, Missouri, United States

and more 5 locations

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

Phase 2
Completed
Conditions
Molluscum Contagiosum
Interventions
Drug: VBP-245 Topical Gel
Drug: Vehicle
First Posted Date
2017-03-13
Last Posted Date
2018-10-11
Lead Sponsor
Veloce BioPharma LLC
Target Recruit Count
110
Registration Number
NCT03077750
Locations
🇺🇸

Philadelphia Institute of Dermatology, Fort Washington, Pennsylvania, United States

🇺🇸

Parkside Pediatrics, Greenville, South Carolina, United States

🇺🇸

Coastal Pediatrics, Mount Pleasant, South Carolina, United States

ALC-919 For The Treatment Of Common Warts

Phase 2
Completed
Conditions
Verruca Vulgaris
Interventions
Drug: Vehicle-Control Topical Solution
First Posted Date
2015-06-29
Last Posted Date
2016-03-09
Lead Sponsor
Veloce BioPharma LLC
Target Recruit Count
21
Registration Number
NCT02483455
Locations
🇺🇸

Philadelphia Institute of Dermatology, Fort Washington, Pennsylvania, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.